Imagine a medical sticker that sticks securely but peels off like a gentle water-based film instead of ripping your skin. Current medical glues often cause painful rashes and sores, especially for people using long-term devices. This new material uses the skin's own natural properties to bond, making it safe, recyclable, and much kinder to the body.
Conventional medical adhesives cause skin injuries in up to 25% of wound care cases, leading to higher infection risks and significant healthcare costs. This creates a burden for patients and generates substantial medical waste.
A patented, glueless, bio-based medical adhesive that uses a water-based bond to attach devices to skin without causing injury.
If you are a device manufacturer dealing with patient complaints about skin damage—this project developed a glueless, bio-based adhesive that prevents injuries for the 8 million people globally using ostomy pouches. It ensures secure adhesion while allowing atraumatic removal.
If you are a dressing producer dealing with the 25% of wound care cases that suffer from adhesive-related injuries—this project developed a water-based bond that reduces inflammation and infection risk. This improves patient adherence and reduces the need for unplanned dressing changes.
If you are a wearable tech company dealing with skin irritation from long-term sensor attachment—this project developed a skin-friendly biomaterial that replaces silicones and acrylates. It allows for secure, medical-grade attachment without the petrochemical drawbacks.
The project describes the adhesive as a cost-effective solution that reduces healthcare costs by minimizing unplanned dressing changes and waste management expenses.
The product will be commercialized under license to medical adhesive and external medical device manufacturers to enable integration into existing and next-generation products.
The technology is patented and will be sold under license to manufacturers in the sector.
Based on available project data, it is designed to be integrated into existing and next-generation products, de-risking the adoption of bio-based materials.
The market potential is estimated to be over 250 million EUR by 2030.
The project is led by a single Portuguese SME, BESTHEALTH4U LDA, with a 100% industry ratio. This lean structure suggests a highly focused commercial drive, as the coordinator is the sole entity responsible for the patented technology and its licensing strategy.
Contact BESTHEALTH4U LDA in Portugal regarding licensing opportunities.
Contact us to facilitate a licensing partnership with Bio2Skin.
